303 Hegenberger Rd., Suite 312
14 articles with OrthoTrophix
TPX-100: OrthoTrophix Published a New Research Article Demonstrating Disease Modification in Knee Osteoarthritis
OrthoTrophix, Inc., a privately held biopharmaceutical company, announced that the Company and its collaborators have published a new research article presenting clinical data demonstrating disease modification in knee osteoarthritis patients treated with TPX-100, the Company's leading candidate for a Disease Modifying Osteoarthritis Drug.
TPX-100: OrthoTrophix Presents More Evidence for Disease Modification in Knee Osteoarthritis in a New Abstract Published in Osteoarthritis & Cartilage Journal
OrthoTrophix, Inc. announced that the Company has demonstrated more evidence for disease modification in knee osteoarthritis patients treated with TPX-100, the Company's leading candidate for a Disease Modifying Osteoarthritis Drug.
OrthoTrophix, Inc. announced that the Company has demonstrated evidence for disease modification in knee osteoarthritis in patients treated with TPX-100, the Company's leading candidate for a Disease Modifying Osteoarthritis Drug.
Demonstrating Significant Correlation between Knee Function Improvement and Cartilage Thickness Increase/Stabilization after TPX-100
Reduction in Pathological Bone Shape Change Correlates with Decreased Frequency of Knee Pain After TPX-100 Treatment
Bone shape analyses were performed by international leaders in joint structure assessment for knee OA, blind to treatment assignment and clinical data.
Previous analysis demonstrated robust and statistically significant clinical benefits of the drug in moderate to severe knee OA.
OrthoTrophix Presents Knee Cartilage Structure Modification Data of TPX-100 at American College of Rheumatology Annual Meeting
OrthoTrophix, a privately held biopharmaceutical company, announced today that the company and its collaborators presented the Phase 2 clinical study data of TPX-100 demonstrating structural improvement of knee cartilage associated with robust knee function improvement in knee osteoarthritis (OA) patients at the American College of Rheumatology (ACR/ARHP) Annual Meeting in Chicago, IL
Clinical Benefits of TPX-100 in Knee Osteoarthritis Patients are Associated with Improvements in Knee Cartilage Structure Modification
OrthoTrophix presented primary results of A Randomized, Double-blind, Placebo-controlled, Multi-dose Phase 2 Study Evaluating the Safety and Efficacy of Intra-articular Injections of TPX-100 in Subjects with Mild to Moderate Patello-Femoral Osteoarthritis Involving Both Knees at the most recent American College of Rheumatology meeting
OrthoTrophix Will Present Data on Long-Term Clinical Benefit of TPX-100 in Mild to Severe Knee Osteoarthritis Patients at OARSI Annual Meeting 2018
OrthoTrophix, Inc., a privately held biopharmaceutical company, announced today that the company plans to report long-term clinical benefits in mild to severe knee osteoarthritis (OA) patients who were treated with TPX-100 at the 2018 OARSI annual meeting (Liverpool, U.K., 26-29 April 2018).
OrthoTrophix Presents the Key Data of the TPX-100 Phase II Study as a Late Breaking Abstract at American College of Rheumatology Annual Meeting
Based on this double-blinded, placebo-controlled, multi-center study, data are presented from 93 subjects with bilateral knee OA who received 4 weekly doses of TPX-100 by intra-articular administration in one knee and identical placebo injections in the other, with at least one follow-up evaluation at 6 and 12 months.
OrthoTrophix Release: Significant Improvements In Knee Function After TPX-100 Administration In A Double-Blind, Placebo-Controlled Phase 2 Study Of Knee Osteoarthritis
OrthoTrophix Completed Subject Enrollment Of The Phase 2 Clinical Trial Of A New Cartilage Repair Therapeutic For Knee Osteoarthritis
OrthoTrophix Completed Patient Treatments In Part A Of The Phase 2 Clinical Trial Of A New Cartilage Repair Therapeutic For Knee Osteoarthritis And Initiated Patient Enrollment For Part B
OrthoTrophix Initiated Phase 2 Clinical Trial Of A New Cartilage Repair Therapeutic For Knee Osteoarthritis And Closed Series A Financing